Skip to main content
. 2018 Feb 6;9:173. doi: 10.3389/fimmu.2018.00173

Figure 3.

Figure 3

MicroRNA (miR)-146a and miR-155 expression in healthy control (HC) pre-treated with interleukin (IL)-1β, tumor necrosis factor (TNF), and thapsigargin (Tg). Pre-treatment of HC dermal fibroblasts (n = 4) with IL-1β (10 ng/mL), TNF (10 ng/mL), and Tg (300 nM). Expression of miR-146a (upper graph) and miR-155 (lower graph) was measured by Taqman qPCR, with and without the addition of the inositol-requiring enzyme 1 inhibitor 4u8C (50 µM). The two-way ANOVA (p = ≤ 0.05) test was used to determine statistical significance.